Volume 1, Issue 6


Cover Image

Cover Figure: Quantification and three-dimensional microanatomical organization of the bone marrow.
See the article by Nombela-Arrieta and Manz.

Join the discussion @ Blood Advances Community Conversations

WASHINGTON, February 14,  2017 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

In the developing world, noncommunicable diseases such as cancer, anemia, and heart disease will likely become more common than infectious diseases as causes of mortality. In the Blood Advances Talk in this issue, Bhatt discusses this emerging challenge as well as potential solutions utilizing advanced technology to consider.

One of the most important advances in the field of hematopoietic cell transplantation has been the development of alternative donor sources so that there are multiple options for patients who could benefit from this treatment approach. In our Point-Counterpoint discussion in this issue, the source of hematopoietic cells of either haploidentical vs matched unrelated donors is debated by Fuchs and Shaw. Please post your comments!

The pathogenesis of graft-versus-host disease after allogeneic transplantation has been an area of intense investigation. Recent evidence has demonstrated a role for Th17 cells in the pathogenesis of this disorder. Using clever technology of "fate mapping" mice, Gartlan et al explore the role of Th17 cells dependent upon interleukin-6 at early time points after allogeneic transplantation. Immunosuppressive medications such as cyclosporine are shown to influence the biology of these cell populations in interesting ways in both mice and humans.

Erdheim-Chester disease (ECD) is a rare but life-threatening malignancy characterized by multiorgan involvement with foamy macrophages with a characteristic immunophenotype. The report by Estrada-Veras et al characterizes 60 patients with ECD from the National Institutes of Health, highlighting the clinical and molecular variability of this disease. The identification of mutations in the BRAF and MAPK pathways suggests possible interventions.

Much has been learned about the hematopoietic system that serves as one of the best-characterized organs; however, there are still many unanswered questions. Nombela-Arrieta and Manz review this important area and highlight the use of imaging to gain novel insights into its biological organization and function.

As we age, chromosomal abnormalities become increasingly common. In the study by Machiela et al, chromosomal 20q deletions, one of the most common karyotypic abnormalities in myeloid diseases, are investigated in a large population of cancer patients and cancer-free individuals. These investigators find this abnormality in approximately 0.1% of adults over the age of 50, which is much more common than the frequency of myeloid disorders. This suggests that these findings are tolerated and that additional events must occur in patients who develop myeloid disease. review this important area and highlight the use of imaging to gain novel insights into its biological organization and function.

Featured Visual Abstract

The clinical spectrum of Erdheim-Chester disease: an observational cohort study

Juvianee I. Estrada-Veras, Kevin J. O’Brien, Louisa C. Boyd, Rahul H. Dave, Benjamin H. Durham, Liqiang Xi, Ashkan A. Malayeri, Marcus Y. Chen, Pamela J. Gardner, Jhonell R. Alvarado Enriquez, Nikeith Shah, Omar Abdel-Wahab, Bernadette R. Gochuico, Mark Raffeld, Elaine S. Jaffe, William A. Gahl





Blood Advances is the official open-access journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.